8-K: scPharmaceuticals Reports 99% FUROSCIX Revenue Growth

scPharmaceuticals Inc. announced strong second quarter 2025 financial results, driven by a 99% increase in FUROSCIX net revenue and significant growth in doses shipped.

Summary

• Generated net FUROSCIX revenue of $16.0 million in Q2 2025, a 99% increase compared to $8.1 million in Q2 2024.
• Approximately 20,200 FUROSCIX doses were filled in Q2 2025, up 117% from 9,300 doses in Q2 2024.
• Sales to Integrated Delivery Networks (IDNs) increased by 70% in Q2 2025 compared to Q1 2025.
• The gross-to-net (GTN) discount for FUROSCIX was 27% in Q2 2025, up from 23% in Q1 2025.
• Approximately 4,700 unique prescribers have prescribed FUROSCIX since its launch through the end of Q2 2025.
• The company formally launched FUROSCIX for the treatment of edema in patients with Chronic Kidney Disease (CKD) in late April 2025, with nephrologists now writing prescriptions.
• The 80mg/1mL FUROSCIX Autoinjector (SCP-111 program) is on track for a targeted supplemental New Drug Application (sNDA) filing in Q3 2025, designed to reduce administration time from five hours to less than ten seconds.
• The Centers for Medicare and Medicaid Services (CMS) proposed the Ambulatory Specialty Model (ASM) on July 14, 2025, which is expected to be a tailwind for FUROSCIX uptake by shifting accountability for unplanned heart failure hospitalizations to clinical specialists.

Sentiment

Score: 7

Explanation: The sentiment is positive due to exceptional revenue and dose growth for FUROSCIX, successful expansion into the CKD market, and the autoinjector development being on track. These operational achievements are strong indicators of commercial success and future potential. However, the increasing net loss and significant cash burn temper the overall sentiment, indicating ongoing financial challenges typical of a growth-stage biotech.

Positives

• Net FUROSCIX revenue grew by 99% year-over-year to $16.0 million in Q2 2025, indicating strong market adoption.
• FUROSCIX doses filled increased by 117% year-over-year to approximately 20,200, demonstrating significant patient uptake.
• Sales to Integrated Delivery Networks (IDNs) saw a 70% increase quarter-over-quarter, highlighting successful penetration into key healthcare systems.
• The formal launch of FUROSCIX for Chronic Kidney Disease (CKD) in late April 2025 expands the addressable market and is already generating prescriptions from nephrologists.
• The 80mg/1mL FUROSCIX Autoinjector program is on track for sNDA submission in Q3 2025, promising a significant reduction in administration time and improved patient convenience.
• The proposed Ambulatory Specialty Model (ASM) by CMS is anticipated to be a positive catalyst for FUROSCIX adoption by incentivizing early intervention for heart failure symptoms.

Negatives

• Net loss increased to $18.0 million in Q2 2025 from $17.1 million in Q2 2024.
• Cash and cash equivalents decreased significantly to $40.8 million as of June 30, 2025, from $75.655 million as of December 31, 2024, indicating substantial cash burn.
• The gross-to-net (GTN) discount increased to 27% in Q2 2025 from 23% in Q1 2025, which reduces net revenue per dose.
• Operating expenses increased across all categories: Cost of product revenues rose to $5.0 million, R&D expenses to $4.1 million, and SG&A expenses to $21.2 million in Q2 2025 compared to Q2 2024.

Risks

• Dependence on the commercial success of FUROSCIX and, if approved, other product candidates.
• Risks associated with receiving regulatory approval for product candidates.
• Risks related to the ability to manufacture or for third parties to deliver sufficient product for commercialization.
• History of significant operating losses and expectation of incurring significant and increasing losses for the foreseeable future, with no guarantee of achieving or maintaining profitability.
• Potential need for additional funding and the risk of being unable to raise capital when needed, which could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Restrictions on operating and financial flexibility imposed by the terms of the credit facility and revenue participation financing facility.
• Clinical and preclinical development processes are lengthy, expensive, and have uncertain outcomes, with potential for difficulties, delays, or termination of trials.
• The risk that global economic factors and uncertainties will impact the company's operations.

Future Outlook

The company anticipates continued momentum for FUROSCIX, driven by increasing prescriber adoption and the recent expansion into the chronic kidney disease market. The 80mg/1mL FUROSCIX Autoinjector is on track for a supplemental New Drug Application (sNDA) filing in Q3 2025, which is expected to significantly improve patient convenience and potentially increase adoption. The proposed Ambulatory Specialty Model (ASM) by CMS is viewed as a potential tailwind for FUROSCIX uptake by encouraging early intervention for heart failure symptoms.

Management Comments

• "We're very pleased with the continued momentum behind FUROSCIX, with net revenue of $16 million in the second quarter. We believe this growth reflects strong execution across our organization and increasing adoption by prescribers who recognize the clinical and economic value that FUROSCIX brings to patient care."
• "Expanding FUROSCIX into the chronic kidney disease (CKD) market represents a critical step forward in our mission to transform how diuretic therapy is delivered. Nephrologists are on the front lines of managing fluid overload in their CKD patients, both with and without concomitant heart failure, and we believe FUROSCIX offers them a much-needed tool to address this challenge."
• "We are encouraged that the Ambulatory Specialty Model (ASM), aimed at improving the upstream management of heart failure, was proposed in the 2026 Physician Fee Schedule by the Centers for Medicare and Medicaid Services on July 14, 2025. By shifting accountability from the hospital to the clinical specialist for all unplanned heart failure hospitalizations, not just 30-day readmissions, with a specific reference to early intervention for worsening symptoms, we believe that this new ASM program has the potential to be a tailwind to the already successful uptake for FUROSCIX."

Industry Context

The announcement highlights scPharmaceuticals' strategic focus on cardiorenal healthcare, a significant and growing market. The expansion of FUROSCIX into the chronic kidney disease (CKD) indication positions the company to address a broader patient population with fluid overload, a common complication in CKD. The development of the autoinjector aligns with a broader industry trend towards patient-centric, home-based care solutions, aiming to reduce healthcare costs and improve patient convenience. The proposed Ambulatory Specialty Model (ASM) by CMS reflects a shift in healthcare policy towards value-based care and preventative measures for chronic conditions like heart failure, which could significantly benefit therapies like FUROSCIX that enable early intervention outside of hospital settings.

Comparison to Industry Standards

• NA

Stakeholder Impact

• **Shareholders:** Potential for increased value due to strong product revenue growth and market expansion, but also risk from continued operating losses and cash burn, potentially leading to future dilution from capital raises.
• **Patients:** Improved access to FUROSCIX for edema treatment, especially with the new CKD indication and the upcoming autoinjector designed for easier home administration.
• **Prescribers (Cardiologists, Nephrologists):** FUROSCIX offers a new tool for managing fluid overload, particularly in CKD patients, and the autoinjector could simplify treatment protocols.
• **Employees:** Continued growth and development of new products suggest job stability and potential for expansion within the company.
• **Creditors:** The company's significant operating losses and cash burn, alongside existing credit facilities, indicate ongoing financial risk that creditors will monitor.

Next Steps

• Host an investor conference call and webcast on August 7, 2025, at 4:30 p.m. ET to review Q2 2025 results.
• Targeted sNDA filing for the 80mg/1mL FUROSCIX Autoinjector in Q3 2025.
• Continue commercial strategy for FUROSCIX, including expansion efforts in the CKD market.
• Monitor the impact of the proposed Ambulatory Specialty Model (ASM) on FUROSCIX uptake.

Key Dates

Recommendation

The company demonstrates strong commercial execution with significant revenue and dose growth for FUROSCIX, successful market expansion into CKD, and a promising autoinjector in the pipeline. These operational achievements are highly positive for a growth-stage pharmaceutical company. However, the increasing net loss and substantial cash burn are notable concerns, indicating that profitability remains distant and future capital raises are likely. While the growth trajectory is compelling, the financial burn rate warrants a cautious approach. A 'hold' recommendation acknowledges the strong product performance and strategic progress while recognizing the financial risks and the need for continued funding.

Keywords

scPharmaceuticals, FUROSCIX, Cardiorenal Healthcare, Heart Failure, Chronic Kidney Disease, Edema, Autoinjector, Pharmaceuticals, Biotech, SEC Filing, Q2 2025 Earnings, Drug Delivery